The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy
- PMID: 22475315
- DOI: 10.1016/j.thromres.2012.03.007
The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy
Abstract
Background: Low-molecular-weight heparins (LMWH) are the most commonly used anticoagulant during pregnancy for prevention or treatment of VTE. However, the size of the associated risk of postpartum haemorrhage (PPH) is unknown.
Objective: To assess the bleeding risk of high dose LMWH, also in relation to time between last dose LMWH and delivery.
Material and methods: From 1999 to 2009, we followed 88 pregnant women who were started on therapeutic anticoagulation. Controls were pregnant women without LMWH, matched 1:4 for parity, mode of delivery, age, gestational age and delivery date. PPH was defined as >500 ml blood loss for vaginal delivery (severe PPH in vaginal delivery as >1000 ml) and >1000 ml for cesarean section (CS). Women were divided into subgroups by the interval between last dose of anticoagulation and delivery (<12, 12-24 hrs, >24 hrs).
Results: Risk of PPH after vaginal delivery was 30% and 18% for LMWH-users and non-users, respectively (OR 1.9, 95%CI 1.1-3.5). Risk of severe PPH after vaginal delivery was not different (5.6 vs 5.0%; OR 1.1; 0.4-3.6). Risk of PPH after CS was 12% in LMWH-users and 4% in non-users (OR 2.9; 0.5-19.4). Both events of LMWH-users occurred after emergency CS. The risk of PPH associated with delivery within 24 hours after last dose of LMWH was 1.2 fold higher (95%CI 0.4-3.6) compared to a larger interval.
Conclusion: High dose LMWH carries an increased risk of more than 500 mL blood loss after vaginal delivery. However, this results not in more clinical relevant severe PPHs. The interval between last dose of LMWH and delivery does not influence the risk of PPH.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Low-molecular-weight heparin in pregnancy: peripartum bleeding complications.J Perinatol. 2007 Jun;27(6):329-34. doi: 10.1038/sj.jp.7211745. Epub 2007 Apr 19. J Perinatol. 2007. PMID: 17443203
-
[Thromboprophylaxis with low-molecular-weight heparin insufficient in high-risk pregnancy].Ned Tijdschr Geneeskd. 2011;155:A3433. Ned Tijdschr Geneeskd. 2011. PMID: 21527059 Dutch.
-
The incidence and risk factors of recurrent venous thromboembolism during pregnancy.Thromb Res. 2014 Aug;134(2):240-5. doi: 10.1016/j.thromres.2014.04.026. Epub 2014 May 2. Thromb Res. 2014. PMID: 24835671
-
[Thromboprophylaxis during pregnancy and the puerperium: highlights from current guidelines].Z Geburtshilfe Neonatol. 2010 Dec;214(6):217-28. doi: 10.1055/s-0030-1269861. Epub 2011 Jan 4. Z Geburtshilfe Neonatol. 2010. PMID: 21207321 Review. German.
-
[Thrombophilia, preeclampsia and other pregnancy complications].Acta Med Croatica. 2009 Oct;63(4):297-305. Acta Med Croatica. 2009. PMID: 20034330 Review. Croatian.
Cited by
-
Does Use of Low-Molecular-Weight Heparin during Pregnancy Influence the Risk of Prolonged Labor: A Population-Based Cohort Study.PLoS One. 2015 Oct 14;10(10):e0140422. doi: 10.1371/journal.pone.0140422. eCollection 2015. PLoS One. 2015. PMID: 26465918 Free PMC article.
-
Risk factors for severe postpartum hemorrhage: a case-control study.BMC Pregnancy Childbirth. 2017 Jan 10;17(1):17. doi: 10.1186/s12884-016-1217-0. BMC Pregnancy Childbirth. 2017. PMID: 28068990 Free PMC article.
-
Bleeding and thrombotic risk in pregnant women with Fontan physiology.Heart. 2021 Sep;107(17):1390-1397. doi: 10.1136/heartjnl-2020-317397. Epub 2020 Nov 24. Heart. 2021. PMID: 33234672 Free PMC article.
-
Role of Low Molecular Weight Heparin in the Management of Unexplained Recurrent Pregnancy Loss: A Review of Literature.Cureus. 2020 Oct 15;12(10):e10956. doi: 10.7759/cureus.10956. Cureus. 2020. PMID: 33083161 Free PMC article. Review.
-
Updated recommendations for the treatment of venous thromboembolism.Blood Res. 2021 Mar 31;56(1):6-16. doi: 10.5045/br.2021.2020083. Blood Res. 2021. PMID: 33627521 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical